Zolvix

1 x 1 l

Oral solution

Active substance

Monepantel : 25 mg/ml

ATC code

QP52AX09 Monepantel

QP52AX Other anthelmintic agents

QP52A Anthelmintics

QP52 Anthelmintics

QP Antiparasitic products, insecticides and repellents

Species

Sheep.

Indications

ZOLVIX oral solution is a broad spectrum anthelmintic for the treatment of gastro-intestinal nematode infections and associated diseases in sheep including lambs, hoggets, breeding rams and ewes.

Spectrum of activity includes fourth larvae and adults of:

Haemonchus contortus*
Teladorsagia circumcincta*
Teladorsagia trifurcata*
Teladorsagia davtiani*
Trichostrongylus axei*
Trichostrongylus colubriformis
Trichostrongylus vitrinus
Cooperia curticei
Cooperia oncophora
Nematodirus battus
Nematodirus filicollis
Nematodirus spathiger
Chabertia ovina
Oesophagostomum venulosum

*including inhibited larvae

Dose to be administered and administration route

The dose is 2.5 mg/kg bodyweight of monepantel.
The veterinary medicinal product is administered as a single treatment. However, the administration may be repeated The need for and frequency of re-treatment(s) should be based on professional advice and should take into account the local epidemiological situation and the animal’s lifestyle.

It is recommended that veterinary medicinal product is used not more than twice in one year.

Underdosing could result in ineffective use and may favour resistance development. To ensure a correct dosage, body weight should be determined as accurately as possible. If animals are to be treated collectively, reasonably homogeneous groups should be set up, and all animals of a group should be dosed at the rate corresponding to the heaviest one.

The use of suitably calibrated measuring equipment is recommended.
Accuracy of the dosing device should be thoroughly checked.

To assure complete swallowing of this low volume solution, administer orally on the back of the tongue. Drenching equipment should be cleaned after use.

Dose table:

Adverse reactions

Target species: sheep

None.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also the last section of the package leaflet for contact details.